Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy for duchenne MD: Long-Term safety check begins

NCT ID NCT06491927

ENROLLING_BY_INVITATION Disease control Sponsor: REGENXBIO Inc. Source: ClinicalTrials.gov ↗

First seen Feb 26, 2026 · Last updated May 21, 2026 · Updated 11 times

Summary

This study follows 66 boys with Duchenne muscular dystrophy who already received RGX-202 gene therapy in an earlier trial. Researchers will monitor safety and track how well the therapy helps with muscle function over time, such as standing, walking, and climbing. The goal is to see if the treatment remains safe and effective in the long run.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72202, United States

  • Stanford School of Medicine /Division of Neuromuscular Medicine

    Palo Alto, California, 94304, United States

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.